Spyre Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYRE research report →
Companywww.spyre.com
Spyre Therapeutics, Inc. , a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
- CEO
- Cameron Turtle
- IPO
- 2016
- Employees
- 73
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $4.34B
- P/E
- -138.56
- P/S
- 47.96
- P/B
- 37.06
- EV/EBITDA
- -21.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -255.97%
- Net Margin
- -198.28%
- ROE
- -31.25%
- ROIC
- -34.12%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-155,203,000 · 25.39%
- EPS
- $-1.98 · 37.74%
- Op Income
- $-209,562,000
- FCF YoY
- -7.52%
Performance & Tape
- 52W High
- $78.80
- 52W Low
- $13.93
- 50D MA
- $59.58
- 200D MA
- $34.59
- Beta
- 3.13
- Avg Volume
- 1.12M
Get TickerSpark's AI analysis on SYRE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | HENDERSON MICHAEL THOMAS | sell | 2,404 |
| May 8, 26 | HENDERSON MICHAEL THOMAS | sell | 33,513 |
| May 8, 26 | HENDERSON MICHAEL THOMAS | sell | 24,814 |
| May 8, 26 | HENDERSON MICHAEL THOMAS | sell | 19,269 |
| May 1, 26 | Burrows Scott L | other | 12,500 |
| May 1, 26 | Burrows Scott L | other | 12,500 |
| May 1, 26 | Burrows Scott L | sell | 12,500 |
| May 1, 26 | Sloan Sheldon | other | 78,333 |
| May 1, 26 | Sloan Sheldon | other | 78,333 |
| May 1, 26 | Sloan Sheldon | sell | 21,306 |
Our SYRE Coverage
We haven't published any research on SYRE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYRE Report →